Fresenius Reveals Denosumab Launch Details As It Settles US Litigation
German Firm Strikes Deal With Amgen Over Prolia/Xgeva Biosimilars
Fresenius Kabi has become the latest biosimilar sponsor to settle US litigation with Amgen over its Prolia/Xgeva rivals. The German firm revealed to Generics Bulletin details of launch dates for its denosumab in both the US and Europe.
